Audentes Therapeutics

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?



Code Company Date Close Change Indicator Value Signal

Trading Performance

Average True Range



Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 3 127.7 0.33% 0.50% 24.9% -8.1% 8.8%
SHORT 2 131.5 0.50% 1.00% 3.2% -22.1% -18.9%


Technical Analysis

Audentes Therapeutics has a TR of 1.07, and an ATR(14) of 1.596.

Average true range (ATR) is a technical analysis volatility indicator originally developed by J. Welles Wilder Jr. for commodities. The indicator does not provide an indication of price trend simply the degree of price volatility.

Calculation: Average True Range (ATR):
1) Current ATR = [(Prior ATR x 13) + Current TR] / 14;
2) Where TR = max[(high-low) abs(high-close previous) abs (low-close previous)]

PROFILE: Audentes Therapeutics (BOLD)

Stock Exchange: NASDAQ
Company: Audentes Therapeutics
Ticker Codes: | BOLD | NASDAQ:BOLD |

About Audentes Therapeutics (NASDAQ:BOLD):

Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. Audentes Therapeutics, Inc. has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. The company was founded in 2012 and is headquartered in San Francisco, California.

Top 10:

Average True Range

Company Close Change(%) Volume Value Signal
NYNY Empire Resorts Inc 9.68 14.6 187,517 0.68 NEUTRAL
DHXM DHX Media Ltd 1.27 12.4 234,932 0.11 NEUTRAL
MCRB Seres Theraptc 3.31 11.4 277,629 0.25 NEUTRAL
TUSK Mammoth Energy Services 4.34 9.6 253,268 0.44 NEUTRAL
BCOM B Communications 1.34 8.1 4,721 0.1 NEUTRAL
NVDA Nvidia Corporation 170.94 7.1 17,914,275 6.6 NEUTRAL
ACIU AC Immune 5.73 6.9 146,621 0.3 NEUTRAL
ACRS Aclaris Therapts 0.93 6.5 1,250,572 0.15 NEUTRAL
NNBR Nn Inc 6.45 6.4 110,947 0.52 NEUTRAL
WYNN Wynn Resorts 112.41 6.3 2,922,585 4.88 NEUTRAL